None listed
Conditions
Brief summary
TITLE : SAFETY AND EFFICACY OF INTRAVITREAL BEVACIZUMAB COMBINED WITH SUPRACHOROIDAL TRIAMCINOLONE IN THE TREATMENT OF CENTRAL RETINAL VEIN OCCLUSION We have planned this study to determine the outcome of central retinal vein occlusion, in terms of decrease in macular edema and increase in visual acuity, after treatment with intravitreal Bevacizumab 0.05ml combined with supra-choroidal triamcinolone 0.05ml and also determines its safety in terms of intra-ocular pressure and infection. OBJECTIVE: To determine the safety and effectiveness of suprachoroidal triamcinolone 0.05ml in combination with intra-vitreal bevacizumab 0.05ml in eyes with central retinal vein occlusion. HYPOTHESIS: Suprachoroidal triamcinolone 0.05ml and intravitreal bevacizumab 0.05ml are both safe and effective when given in combination in the treatment of central retinal vein occlusion. Our study will continue for six months because the patients enrolled in our study in the month of September will need follow up till the month of December, as we have to give total 3 injections, 1 injection of both bevacizumab and triamcinolone every month for three months, and follow them every month and to see the response.
Interventions
In our study we will give intra-vitreal bevacizumab 0.05ml(1.25mg) combined with 0.05ml(2mg) of triamcinolone in supra-choroidal space to determine the outcome of central retinal vein occlusion in terms of decrease in macular edema via ocular coherence tomography and increase in visual acuity by assessing visual acuity via snellen chart. Each injection will be given monthly like 1 injection given at presentation then other will be given after 1 month of that and 3rd injection after 1 month of t
In our study we will give intra-vitreal bevacizumab 0.05ml(1.25mg) combined with 0.05ml(2mg) of triamcinolone in supra-choroidal space to determine the outcome of central retinal vein occlusion in terms of decrease in macular edema via ocular coherence tomography and increase in visual acuity by assessing visual acuity via snellen chart. Each injection will be given monthly like 1 injection given at presentation then other will be given after 1 month of that and 3rd injection after 1 month of the 2nd injection. The patient will be followed on monthly basis for three consecutive months and his macular thickness, visual acuity and intra-ocular pressure will be recorded monthly.
Sponsors
Salahuddin
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1, All those patients diagnosed with central retinal vein occlusion 2, Either gender (male/female)
Exclusion criteria
1, All those patients having poor compliance and follow up 2, All Known glaucomatous or glaucoma suspected patients 3, Eyes with opaque media in which fundus assessment was not possible like, dense cataracts, corneal opacity, vitreous bleed etc. 4, Eyes with prior lasers or injections done. 5, Eyes with complications like neo-vessels on disc and else-where in fundus and anterior segment neo-vessels. 6, Eyes with active inflammation or infection like conjunctivitis etc.
Outcome results
None listed